Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Corcept Therapeutics Incorporated    CORT

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/15/2017 11/16/2017 11/17/2017 11/20/2017 11/21/2017 Date
18.45(c) 19.05(c) 18.39(c) 17.09(c) 17.58(c) Last
1 067 999 1 282 974 927 812 2 209 492 1 259 618 Volume
+1.37% +3.25% -3.46% -7.07% +2.87% Change
More quotes
Financials ($)
Sales 2017 160 M
EBIT 2017 54,1 M
Net income 2017 55,7 M
Debt 2017 -
Yield 2017 -
Sales 2018 240 M
EBIT 2018 111 M
Net income 2018 112 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 40,45
P/E ratio 2018 20,59
Capi. / Sales2017 12,2x
Capi. / Sales2018 8,11x
Capitalization 1 950 M
More Financials
Company
Corcept Therapeutics, Inc. engages in the development of drugs for the treatment of severe psychiatric, neurological, and metabolic disorders.It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol.Its products include korlym and korlym... 
Sector
Pharmaceuticals
Calendar
02/13Earnings Release
More about the company
Surperformance© ratings of Corcept Therapeutics Incor
Trading Rating : Investor Rating :
More Ratings
Latest news on CORCEPT THERAPEUTICS INCOR
11/03 CORCEPT THERAPEUTICS INCORPORATED : INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF ..
11/02 CORCEPT THERAPEUTICS INCORPORATED : misses 3Q profit forecasts
11/02 CORCEPT THERAPEUTICS INC : Regulation FD Disclosure, Financial Statements and Ex..
11/02 Corcept Therapeutics Announces Third Quarter 2017 Financial Results, Raises 2..
10/26 Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Cor..
10/16 CORCEPT THERAPEUTICS INCORPORATED : Today's Research Reports on Trending Tickers..
10/12 CORCEPT THERAPEUTICS INCORPORATED : Data on Clinical Trials and Studies Reported..
08/30 CORCEPT THERAPEUTICS INC : Regulation FD Disclosure (form 8-K)
08/18 CORCEPT THERAPEUTICS INCORPORATED : Today's Research Reports on Trending Tickers..
08/07 CORCEPT THERAPEUTICS INCORPORATED (N : CORT) Files An 8-K Entry into a Material ..
More news
Sector news : Pharmaceuticals - NEC
11/21 Brexit gets real for drugmakers as regulator moves to Amsterdam
11/21 Exclusive - Prescient messages about Indian companies circulate in WhatsApp g..
11/20 ASTRAZENECA : EU drugs agency move to Amsterdam minimizes likely staff losses
11/20 ASTRAZENECA : EU drugs agency move to Amsterdam minimises likely staff losses
11/20 FTSE recoups early losses as cyclicals recover
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
11/07 YOUR DAILY PHARMA SCOOP : Anxious Time For Dynavax Longs, VBL Therapeutics Gets ..
11/06 YOUR DAILY PHARMA SCOOP : Progenics Looks Promising, Big Week For Dynavax, Keryx..
11/03 Corcept's Q3 revenue beat and guidance raise not enough to boost shares, down..
11/02 Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2017 Results - Earning..
11/02 Corcept Therapeutics EPS in-line, beats on revenue
Chart CORCEPT THERAPEUTICS INCOR
Duration : Period :
Corcept Therapeutics Incor Technical Analysis Chart | CORT | US2183521028 | 4-Traders
Technical analysis trends CORCEPT THERAPEUTICS INCOR
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 17,8 $
Spread / Average Target 4,2%
EPS Revisions
Managers
NameTitle
Joseph K. Belanoff President, Chief Executive Officer, Director & MD
James N. Wilson Chairman
Gary Charles Robb Secretary & Chief Financial Officer
Robert S. Fishman Chief Medical Officer
Hazel Hunt Senior Vice President-Research
Sector and Competitors
1st jan.Capitalization (M$)
CORCEPT THERAPEUTICS INCORPORATED135.40%1 950
JOHNSON & JOHNSON19.78%370 552
NOVARTIS11.20%220 012
ROCHE HOLDING LTD.-1.55%212 913
PFIZER8.90%210 711
MERCK AND COMPANY-6.23%147 550